One software platform for pharmacy education and pharmacy governance
AccuRXy is a subscription software business sold on one platform: Educate for pharmacy education and Regulate for medication-incident reporting and pharmacy governance. We start in Ireland and the UK, and the same engine carries us into new markets.
€900k
Seed round
Indicative, to be refined by the costed roadmap
2 products
Educate and Regulate
Distinct buyers, shared product team
7 countries
Feasibility interviews
Educators, deans and pharmacy operators
Medication harm is costly and preventable, yet training and governance remain manual
$42bn
Estimated annual global cost of medication errors
WHO, Medication Without Harm
50%
WHO goal: cut severe avoidable medication harm
Third Global Patient Safety Challenge
2,000
Registered pharmacies in Ireland
PSI, year-end 2025
For educators
- Writing, reviewing and maintaining clinically credible scenarios takes significant staff time
- Students ask for more practice than faculty can build by hand
- The established free tool, MyDispense, sets a low price anchor
For pharmacies
- Regulators advise that all staff are trained to identify, manage and record errors and near misses
- Reporting, follow-up actions, SOPs and training records sit in separate paper and spreadsheet systems
- Owners and superintendents need clear oversight and retrievable evidence for inspection
Simulation is growing fast, pharmacy is going digital, and AI makes content creation practical
Global medical simulation market (USD bn)
MarketsandMarkets projects a 15.3% CAGR, 2026 to 2031. Towards Healthcare independently estimates $3.05bn in 2024 rising to $12.94bn by 2034 (15.5% CAGR). Estimates vary by definition; this is the broader medical simulation market, not pharmacy alone.
- Regulators increasingly allow specified pharmacy records, including controlled-drug registers, to be held electronically where software meets required standards
- Expanding community-pharmacy clinical services create new consultation, governance and training-record needs
- Simulation is established in health professions education; a 2023 ACCP review found positive effects on learner satisfaction, knowledge and skills, while noting more pharmacy-specific outcome studies are needed
- Generative AI can draft scenarios and feedback quickly, with educator review and approval kept in the loop
Two products on one platform, from the classroom to the pharmacy counter
For schools of pharmacy
Educate
AI-assisted creation of medication-safety scenarios, linked questions and explanatory feedback, with educator review and approval before anything reaches a student.
For pharmacies and groups
Regulate
Medication incident and near-miss reporting, investigation, corrective actions, SOPs, inspection readiness and staff development in one connected workflow.
To be precise about scope: Regulate is a reporting and governance system. It does not perform real-time medication-error detection or live prescription checking. A future link between Regulate insights and Educate content could support incident-informed learning, using de-identified or synthetic material.
Educate: less preparation time for educators, more practice for students
Educators
- AI Content Studio to generate, edit, review, publish and version scenarios
- Curriculum alignment by topic, year level and competency area
- Cohorts, assignments with due dates, attempt limits and feedback release
- Class and student analytics with CSV and PDF export
- Evidence Pack traceability showing the source material behind each generation stage
Students
- Immersive scenario player with prescriptions, patient profiles and step-by-step decisions
- Open practice mode for self-paced, ungraded learning
- Optional VR pharmacy mode with queues and distractions
- AI tutor, case study library and personal progress tracking
- Points, levels, badges and a cohort leaderboard
Regulate: one workflow from near miss to corrective action to inspection evidence
Incident and safety
Structured error and near-miss reports, case management with audit trail, root cause analysis, action plans with owners and deadlines, Good Catches, safety alerts and a LASA database.
Governance and compliance
Regulator self-assessment and inspection readiness, CQI meetings, compliance checklists, SOP manager with staff acknowledgement, practice circulars and an inspection evidence export.
Clinical services and learning
Clinical-service records and training tracker, medicines disposal, controlled-drug workflows, training resources, certificates, CPD nudges and ePortfolio drafting.
Five role-based views (staff reporter, superintendent, manager, safety officer, administrator), multi-site organisations, anonymised benchmarking with consent, and AI-assisted capture from free text or photographs, always with human confirmation.
Working product screens from the current build
Patient at counter
Margaret Doyle, 68
Community pharmacy · Dublin
Prescription
Metformin 500 mg tablets
Two tablets twice daily with meals · 56 tablets
What is your first action?
Incident record
Near miss at dispensing
Type
Dispensing error
Severity
No harm
Contributing factors
Illustrative interface views. On-screen figures are examples, not trial outcome measures.
Three founders spanning pharmacy education, medication safety and commercial scale-up

Dr Cathal Cadogan
Co-founder · Pharmacy education
Pharmacist and Associate Professor in Practice of Pharmacy at Trinity College Dublin, with expertise in pharmacy education and medicines optimisation.

Professor Cristín Ryan
Co-founder · Medication safety
Pharmacist and Professor in Practice of Pharmacy at Trinity College Dublin, with expertise in medication safety, professional development and quality improvement.

Andy O’Donoghue
Co-founder · Commercial and technology
Digital health entrepreneur with commercial and technical expertise and a track record of building digitally disruptive businesses from start-up to acquisition.
Technical team
Dr Ian O’Keeffe · Dr Haider Khalid · Dr Saravanabalagi Ramachandran · Birva Mehta · Luciana Medeiros · Greg Carey
Partners and funding
Developed with the School of Pharmacy and Pharmaceutical Sciences at Trinity College Dublin and the Learnovate Centre, supported by an Enterprise Ireland Commercialisation Fund Award.
We compete on workflow, educator control and total customer value
| Player | Segment | What they offer | Our angle |
|---|---|---|---|
| MyDispense (Monash) | Education | Free pharmacy simulation with exercise authoring and assessment | Faster authoring and review workflow, curriculum fit, AI-assisted feedback. Must prove value over a free tool. |
| EHR Go | Education | Pharmacy platform with editable cases, OSCE and simulation. US$128 annual list, usually paid by students | Priced below at €89 / US$89 for trial testing, with free faculty access as a possible message |
| Think Research (Pharmapod) | Pharmacy | Incident case management, analytics, CQI, self-assessment and SOP management. Now part of a Canadian group, so our home markets are secondary to them | Regulator-aligned workflow and content with local support, bringing reporting, actions, clinical-service records and staff learning together in one system |
| AccuRXy | Both | Educate and Regulate on one platform, with human approval and source traceability | Education-to-practice link as the product matures |
Competitor descriptions reflect published offers checked 30 September 2026. Demonstrations and customer conversations will test practical fit before any price comparison is made public.
One price of €89: 55 schools is €1.96m a year, the full global base is €53m
600,000
Global planning base
IPSF represents 600,000+ pharmacy students and recent graduates
22,000
Initial reachable scenario
55 schools averaging 400 students, about 3.7% of the base
Ireland + UK
Initial sales focus
Plus accessible international relationships
| Schools won (400 students each) | Learners | Annual revenue at €89 |
|---|---|---|
| 10 schools | 4,000 | €356k |
| 25 schools | 10,000 | €890k |
| 55 schools, initial scenario | 22,000 | €1.96m |
| Global base, full participation | 600,000 | €53m |
€89 per student per year, held flat: growth comes from schools won, not price rises. Every 10 schools adds about €356k of annual recurring revenue; technician learners are not included.
€89 per student at launch, with €70 as the tested floor and €94 by Year 4 if CPI indexed
Annual price per student (US$)
US$89 is about 30% below EHR Go's US$128 list price and 25% below its 400-licence price. EHR Go usually charges students directly, so it is not proof of a school's budget.
- €89 is the launch price to test, with €70 as the downside floor
- Launch test: €89 in Europe and US$89 in America (separate local prices; the US price yields about 10.8% less per licence at current exchange rates)
- Possible message: faculty access is free, students pay
- What students already pay for one study tool: EHR Go US$128, Osmosis US$249, UWorld NAPLEX QBank from US$299, the RxPrep course US$999. €89 sits below that €115 to €275 band
- These are US list prices paid by students directly, so they show what a student will spend, not what a European faculty budget holds
- Willingness to pay at €89 is the key trial question, not a settled assumption
€3,000 per site per year as a working price
€6.0m
Home-market annual ceiling
2,000 pharmacies at full adoption, €3,000 per site per year
€3,000
Working price per site per year
€250 per month, per site
€150,000
ARR from 50 paying sites
At €3,000 per site per year. That is 2.5% of the home market's 2,000 pharmacies.
- Annual site subscription with group management and volume terms; implementation fees and optional modules priced separately
- Three buyer shapes: a single community pharmacy at the working price; a buying group or professional association contracting for a whole membership; a large online or mail-order operator contracting at group level
- A group agreement still prices per site but on volume terms, so a 200-site deal is a different negotiation from a single site
- Buyers: owners, superintendent pharmacists and group leadership; users: managers, safety officers and staff; workflow fit and existing contracts decide the sale
- Licensed community pharmacies in reach: c. 160,000 across the EU (PGEU), 10,152 in Canada (NAPRA, January 2026) and c. 19,000 independent pharmacies in the US (NCPA), c. 2,000 in Ireland
- At €3,000 a site, the EU's 160,000 community pharmacies are about €480m of annual software value, and Ireland's 2,000 sites about €6m
ARR at illustrative scale
Educate at €89, 400 students per school
Each bar is a school count, not a range: 3 schools is €107k, 5 is €178k, 9 is €320k. The 55 school ceiling of €1.96m is on the market slide.
Regulate at €3,000 per site per year
Single price, no ranges: €150k at 50 sites, €1.5m at 500 and €6.0m at 2,000.
Annualised subscription revenue is the value of a full year of contracted service, which differs from revenue recognised or cash collected in a partial year. Manufacturer-funded education is excluded until a funded use case exists.
Model price and user counts
Educate
Per student, per year
600 licences · €53k a year
Regulate
Per pharmacy site, per year
Deck working price €3,000, inside a €100 to €300 monthly range
Ireland has about 2,000 pharmacies in total
10 sites · €30k a year
Illustrative only: full-year subscription value at list price, before discounts, VAT and implementation fees. Educate assumes one licence per student; Regulate prices a site, not a user.
Year 1 starts on the home-market pilot base: two pharmacy schools and ten sites. Year 3 adds UK schools and groups; by Year 4 Educate covers sixteen schools and Regulate about 500 sites, roughly one in four of Ireland's 1,912 community pharmacies once UK groups are included.
Software economics: one platform, repeatable sales, revenue that compounds
One codebase, many markets
The generation engine, review workflow and evidence layer are shared. Regulatory content sits apart from the software, so a new jurisdiction is a content and compliance task rather than a rebuild.
Content compounds
Every approved scenario, question set and feedback explanation is reused across cohorts and customers, so each additional school adds margin instead of build cost.
Two buyers on one platform
Educate sells seats to schools at €89 per student per year; Regulate sells sites to pharmacies at €3,000 per site per year. Both draw on the same generation, review and evidence services.
Land, then expand
A school starts with one programme and adds year levels; a group starts with a handful of sites and adds the rest under group terms. Expansion happens inside accounts we already hold.
Both products are licence-based, so revenue follows the number of students and sites served rather than delivery hours.
Trials first, then paid contracts
Educate
- Five priority institutions, engaging academic champions and budget holders together
- Target: 3 to 5 institutions expressing intent to pay by August 2027
- Sales case built on measured preparation time, quality and repeat use
- Expect 3 to 6 month university compliance checks; Canada flagged as a more agile decision environment
Regulate
- 3 to 5 buyer conversations by late January 2027; Cara is an active prospect
- Pilot ambition: 2 to 3 organisations and 3 to 5 sites
- At least one documented buying decision by M12 and first paid conversion by M15
- Independent pharmacies and multi-site groups, with pricing refined through use
Pipeline goal: 15 to 20 qualified opportunities across both products by M15, each with a named buyer or champion and an agreed next action. A 5 to 6 member customer advisory board will meet quarterly. One practical partnership (education, distribution or integration) is prioritised; named candidates include Elsevier, Medscape, AMBOSS and Wolters Kluwer.
Ireland and the UK to first revenue, English-speaking schools next, Europe through partners
Now to mid 2027
Ireland and the UK
Home markets. Trials with Trinity, RCSI and Queen's Belfast, then first paid Educate contracts and Regulate pilots. PSI and GPhC aligned content is written once and reused.
Mid 2027 to 2028
Canada and Australia
English-language expansion where interest is already recorded: Toronto and UNSW, with Canada reading as the faster decision environment. Same product, local regulator and curriculum content pack.
2028 to 2029
Netherlands, Belgium, Portugal
Entered through a university or distribution partner rather than a direct sales hire, with translation funded by the partner or the account.
| Market | Evidence already in hand | Entry route | Timing |
|---|---|---|---|
| Ireland | Home institution and pre-pilot group; PSI content and terminology | Direct, founder-led | Now to 2027 |
| United Kingdom | Queen's Belfast support letter and named pilot partner; GPhC framework | Direct with academic champion | Now to 2027 |
| Canada | Toronto interview; faster procurement flagged in the feasibility study | Direct, then partner | 2027 to 2028 |
| Australia | UNSW named as a pilot partner in the feasibility study | Partner-led | 2027 to 2028 |
| Netherlands, Belgium, Portugal | Groningen and Ghent interviews, Lisbon support letter and case-sharing interest | University partner, translated content | 2028 to 2029 |
Each market is a content and compliance task rather than an engineering one, so entry is gated on evidence from the preceding phase and costed market by market. Base-case revenue assumes Ireland and the UK only; Canada, Australia and Europe are upside, not forecast.
Early validation from educators and pharmacy operators across seven countries
“Our students are always asking for more opportunities to practice.”
“If you create a system which generates those cases and they are linked with guidelines, that would be really helpful.”
“If anyone can figure out how to help with simulations in pharmacy at a large scale, there’s benefit.”
“A super idea… a quick win, a quick show of value.”
Feasibility interviews (May 2025) covered Ireland, the UK, Australia, Canada, the Netherlands, Belgium and Portugal. Support letters are recorded from QUB, RCSI and Lisbon. These are qualitative signals, not purchase commitments; the trial programme is designed to convert them into evidence.
Eight institutions across seven countries, with pilot partners already named
8
Institutions engaged
7
Countries represented
3
Written letters of support
Queen’s University Belfast, RCSI and the University of Lisbon
| Institution | Country | Engagement | Focus |
|---|---|---|---|
| Trinity College Dublin | Ireland | Home institution; pre-pilot group | Scenario research and Trial 0.5 usability |
| RCSI | Ireland | Support letter; pilot partner | Academic pilot deployment |
| Queen’s University Belfast | United Kingdom | Support letter; pilot partner | Academic pilot deployment |
| University of Lisbon | Portugal | Interview; support letter | Case sharing and adaptive content |
| Ghent University | Belgium | Interview | Educator authoring workload |
| University of Groningen | Netherlands | Interview | Guideline-linked cases |
| University of Toronto | Canada | Interview | Access to simulation at scale |
| UNSW | Australia | Pilot partner named in the feasibility study | Academic pilot deployment |
Engagement is qualitative at this stage: interviews, written support and named pilot partners. No institution has committed to purchase. The trial programme is designed to convert this into measured and priced evidence.
Four staged trials generate the evidence buyers need
| Trial | Who | When (provisional) | What it tests |
|---|---|---|---|
| 0.5 Pre-pilot | Small TCD group, one clinical area | Before Christmas 2026 or January 2027 | Usability, unstructured feedback |
| 1 Academic | Educators and students | January or February 2027 | Scenario quality and educator effort |
| 2 Broad academic | Educators (Jun to Aug), students (Sep 2027) | Summer and September 2027 | Preparation time, quality, learner experience (Likert scales), willingness to pay |
| 3 Regulate | One organisation, two sites, about 20 participants | February 2027 | Near-miss capture, LASA usability, fit with existing processes |
Dates are indicative pending AI delivery estimates and approvals. No patient names or records are captured; the ethics route is being explored and a data-protection review will determine DPIA requirements.
June 2026 to September 2027: from trials to first paid conversions
Oct 2026
Trial scope, AI estimates, evaluation requirements, priority accounts
Nov to Dec 2026
Approved scenarios, guides, pricing discovery, investor preparation
Dec 2026 to Jan 2027
Trial 0.5; manufacturer-education decision point (Jan); 3 to 5 Regulate buyer conversations
Jan to Feb 2027
Trial 1 (academic) and Trial 3 (Regulate)
Q2 2027
8 to 12 substantive investor conversations
Jun to Aug 2027
Educator Trial 2; funding discussions; costed business model and go-to-market plan
Aug 2027
3 to 5 institutions expressing intent to pay
Sep 2027
Student Trial 2; Q4 contingency for funding close
Targets: documented Regulate buying decision by M12; initial paid conversion by M15.
Development is largely built; the next phase measures production costs and margins
Cost structure being modelled
- AI generation, AI feedback, storage, review and support per scenario and per site
- Developer tooling and LLM spend, already tracked by the technical lead
- Staffing, licences, onboarding, legal and IP, sales
- Customer success capacity, hired against workload and funding
How margins are protected
- Reuse of approved scenarios to reduce repeat generation cost
- Usage limits and package definitions set from measured costs
- Implementation and optional modules priced separately
- Project funding separated from company costs in the model
Seeking €900k at Seed
20–30
Target investors identified
8–12
Substantive conversations by Q2 2027
Jun–Aug 2027
Target close window
Contingency: Q4 2027
Investor routes
- Enterprise Ireland PSSF
- Mainstream venture capital
- Spin-out funds (TCD spin-out arrangements being prepared)
- Specialty VC, for example Wake-Up Capital
Use of funds (indicative)
Trial delivery, engineering capacity, production security and compliance
Educator and pharmacy sales, customer success, partner channel
Patent filing, freedom to operate, record acceptance, working capital
Indicative split of the €900k seed, refined through the costed roadmap and runway plan.
Key risks and how we are addressing them
| Risk | Mitigation |
|---|---|
| A free incumbent (MyDispense) anchors academic price expectations | Compete on authoring and review workflow, educator control and curriculum fit; trials measure time saved; test €89 launch price and free faculty access |
| Price acceptance at €89 per student and €3,000 per site is untested | Ask every trial completer about budget, authority and timing; test both price points in live conversations; add packages if resistance appears |
| Slow university procurement (3 to 6 months) | Start compliance conversations during trials; target intent to pay by August 2027 |
| Pharmacy buyers distrust AI or resist new tools | Human approval and traceable sources; Regulate positioned as reporting and governance, not automated checking |
| RL Datix already serves incident reporting | Differentiate on regulator-aligned workflow fit, usability and combined reporting, governance and learning |
| AI delivery and cost uncertainty | AI estimates in October; measure production cost per scenario; usage limits |
| Data protection and statutory record requirements | No patient names or records in trials; DPIA review; acceptance against regulator electronic-record requirements before CD register deployment |
Protecting the scenario engine and building for regulated buyers
Intellectual property
- Provisional patent to be considered for the AI-generated scenario engine (personalisation, guideline adaptation, feedback)
- Freedom-to-operate analysis advised before commercial launch; prior art reviewed in medication-safety decision support
- Core adaptive case logic and scoring treated as trade secrets until patentability is confirmed
- Spin-out arrangements with TCD being prepared
Governance and compliance
- Evidence Pack traceability, validation and human approval for every scenario
- GDPR-aligned design, private evidence storage, per-record audit trails
- Role-based access and consent-managed benchmarking
- Legal and regulatory requirements built into production acceptance
A software business with two recurring revenue lines and a costed route to first contracts
- A regulated, quantified need: $42bn annual cost of medication errors and a WHO goal to halve severe avoidable harm
- Subscription revenue from two buyers on one platform: €89 per student per year and €3,000 per pharmacy site per year
- Built to travel: shared engine and review workflow, jurisdiction-specific content, and interest already recorded across seven countries
- Revenue ladders already mapped: €107k to €178k from 3 to 5 schools, €150k from 50 pharmacies, against €42m to €54m academic and €6.0m home-market ceilings
- De-risked spend: product largely built, four trials to convert interest into contracts, intent to pay by August 2027
Sources and basis of figures
- WHO, Medication Without Harm
- MarketsandMarkets, Medical Simulation Market 2026 to 2031
- Towards Healthcare, Healthcare Simulation Market
- ACCP review, simulation in pharmacy education (McBane et al., 2023)
- PSI, Advice on Medication Error Management
- PSI, Record-keeping in retail pharmacy businesses
- PSI, Common Conditions Service
- IPSF
- Monash University, MyDispense
- Think Research (Pharmapod), Community Pharmacies
- PGEU, Europe's 160,000 community pharmacies
- NAPRA, national statistics of licensed pharmacies (Canada, 2026)
- NCPA, independent community pharmacies (US)
- WHO, Patient safety incident reporting and learning systems
Internal figures come from the AccuRXy Commercial Report (V33), the Educate pricing discussion (October 2026) and the May 2025 feasibility study. Where the earlier study described real-time error detection, this deck follows the later commercial report, which scopes Regulate as reporting and governance. Market-size figures differ by source and definition. Revenue figures are modelled scenarios, not forecasts or commitments.
Regulate: professional user's dashboard
Safety dashboard
Ballymount Pharmacy · reporting period: this quarter
24
Reports this quarter
7
Open actions
1
Overdue
86%
Closed on time
Layout reconstructed from the live build at accurxy2.redcert.com, whose public entry point is the sign-in screen. Menu: safety dashboard, report incident, my reports, action plans, error analytics, SOP library, inspection preparation, team and roles, settings. On-screen names, references and figures are illustrative, not trial data.
